Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy

HPB

Volumn 14, Issue 6, 2012, Pages 365-372

  Tzeng, Ching Wei D ^a   Fleming, Jason B ^a   Lee, Jeffrey E ^a   Wang, Xuemei ^a   Pisters, Peter W T ^a   Vauthey, Jean Nicolas ^a   Varadhachary, Gauri ^a   Wolff, Robert A ^a   Katz, Matthew H G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

pancreatic adenocarcinoma; pancreaticoduodenectomy; recurrence; surveillance; survival; symptoms

Indexed keywords

CAPECITABINE; FLUOROURACIL; GEMCITABINE;

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMATOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PERFORMANCE; RETROSPECTIVE STUDY; SURVIVAL;

EID: 84862792610     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00445.x     Document Type: Conference Paper

References (28)

1. Baca B, Beart RW Jr, Etzioni DA,. (2011) Surveillance after colorectal cancer resection: a systematic review. Dis Colon Rectum 54: 1036-1048.
2. Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, Bessa X, et al,. (2006) Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicentre, randomized, controlled trial. J Clin Oncol 24: 386-393. (Pubitemid 46630457)
3. Renehan AG, Egger M, Saunders MP, O'Dwyer ST,. (2002) Impact on survival of intensive follow-up after curative resection for colorectal cancer: systematic review and meta-analysis of randomized trials. BMJ 324: 813-820.
4. Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al,. (2005) Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev (1): CD001768.
5. Bennett JJ, Gonen M, D'Angelica M, Jaques DP, Brennan MF, Coit DG,. (2005) Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? J Am Coll Surg 201: 503-510. (Pubitemid 41393070)
6. Salerni G, Lovatto L, Carrera C, Puig S, Malvehy J,. (2011) Melanomas detected in a follow-up programme compared with melanomas referred to a melanoma unit. Arch Dermatol 147: 549-555.
7. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al,. (2009) Longterm survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16: 836-847.
8. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al,. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413. (Pubitemid 27251144)
9. Katz MH, Fleming JB, Lee JE, Pisters PW,. (2010) Current status of adjuvant therapy for pancreatic cancer. Oncologist 15: 1205-1213.
10. Seelig MH, Janot M, Chromik AM, Herzog T, Belyaev O, Weyhe D, et al,. (2009) Redo-surgery following curative resection of pancreatic carcinoma: the difference between true and suspected recurrence. Dig Surg 26: 222-228.
11. Meyers MO, Meszoely IM, Hoffman JP, Watson JC, Ross E, Eisenberg BL, et al,. (2004) Is reporting of recurrence data important in pancreatic cancer? Ann Surg Oncol 11: 304-309. (Pubitemid 40486771)
12. National Comprehensive Cancer Network. (2011) Pancreatic adenocarcinoma V2. In: NCCN Clinical Practice Guidelines in Oncology, 2011.
13. Hwang RF, Wang H, Lara A, Gomez H, Chang T, Sieffert N, et al,. (2008) Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol 15: 1356-1366.
14. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al,. (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206: 833-846; discussion 846-848.
15. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al,. (2008) Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3496-3502.
16. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al,. (2008) Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26: 3487-3495.
17. Aloia TA, Lee JE, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, et al,. (2007) Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 204: 347-355. (Pubitemid 46283494)
18. Yen TW, Abdalla EK, Pisters PW, Evans DB,. (2005) Pancreaticoduodenectomy. In:, Von Hoff DD, Evans DB, Hruban RH, eds. Pancreatic Cancer. Sudbury, MA: Jones & Bartlett, pp. 265-286.
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al,. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655. (Pubitemid 13149996)
20. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al,. (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246: 52-60. (Pubitemid 47012207)
21. Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, et al,. (2012) Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg 16: 68-78.
22. Kiebert GM, Welvaart K, Kievit J,. (1993) Psychological effects of routine follow-up on cancer patients after surgery. Eur J Surg 159: 601-607. (Pubitemid 24002260)
23. Thompson CA, Charlson ME, Schenkein E, Wells MT, Furman RR, Elstrom R, et al,. (2010) Surveillance CT scans are a source of anxiety and fear of recurrence in longterm lymphoma survivors. Ann Oncol 21: 2262-2266.
24. Barugola G, Partelli S, Marcucci S, Sartori N, Capelli P, Bassi C, et al,. (2009) Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol 16: 3316-3322.
25. Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, et al,. (2006) Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107: 2589-2596. (Pubitemid 44845612)
26. Ueno H, Okada S, Okusaka T, Ikeda M,. (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59: 296-301.
27. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al,. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
28. Asiyanbola B, Gleisner A, Herman JM, Choti MA, Wolfgang CL, Swartz M, et al,. (2009) Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-fluorouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg 13: 752-759.